As in prior LCINS studies10, EGFR and TP53 harbored the most driver mutations, with 52.2% and 30.5% mutated in adenocarcinomas, respectively, whereas KRAS was only mutated in 6.5% of samples. This evidence concerns the gene KRAS and adenocarcinoma.